CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment

CG Oncology Inc. (NASDAQ:CGON) is one of the best new stocks to buy right now. On September 17, Morgan Stanley raised the firm’s price target on CG Oncology to $79 from $56, while maintaining an Overweight rating on the shares. Earlier in August, CG Oncology announced significant clinical advancements in its bladder cancer pipeline and financial results for Q2 2025.

The company is focused on developing cretostimogene grenadenorepvec, which is an investigational oncolytic immunotherapy for Non-Muscle Invasive Bladder Cancer/NMIBC. Management’s outlook is supported by a strong cash position and a favorable legal outcome that together are expected to fund operations into the first half of 2028.

CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment

Clinical trial updates highlighted promising data from the BOND-003 Cohort C trial for high-risk NMIBC patients who are unresponsive to BCG treatment. The company also initiated the CORE-008 Cohort CX trial, which is evaluating the combination of cretostimogene and gemcitabine in high-risk NMIBC patients. Upcoming milestones include the completion of Phase 3 enrollment for the PIVOT-006 trial in Q3 and the initiation of a Biologics License Application submission for cretostimogene in Q4.

CG Oncology Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company that develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.

While we acknowledge the potential of CGON to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CGON and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.